Analysis for Crinetics Pharmaceuticals, Inc. (CRNX)

Add CRNX to watchlist(s)

You Should Create a Watchlist In The First Place.

Price Over Time

Profile

Company Name

Crinetics Pharmaceuticals, Inc.

Symbol

CRNX

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, San Diego

Sector

Healthcare

Industry

Biotechnology

Website

https://www.crinetics.com

ISIN

US22663K1079

CIK

1658247

CUSIP

22663K107

UEI

-

LEI

-

Business Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.